Spinal IDH-wildtype glioma: a single center experience of rare disease

Spinal IDH-wildtype glioma: a single center experience of rare disease

Saved in:

Bibliographic Details
Main Authors:	H. Gull, O. Gembruch, L. Rauschenbach, P. Ketelauri, R. Jabbarli, M. Darkwah Oppong, Y. Ahmadipour, U. Sure, N. Özkan
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	Brain and Spine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772529424013614
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes
by: Michael Chang, et al.
Published: (2024-10-01)

Comparative Clinical-Imaging and Histogenetic Analysis Between Astrocytoma IDH-Mutant Grade 4 and Glioblastoma IDH-Wildtype—Is There Really a Worse One?
by: Cristian Ionut Orasanu, et al.
Published: (2025-02-01)

Tumour surface regularity predicts survival and benefit from gross total resection in IDH-wildtype glioblastoma patients
by: Peng Lin, et al.
Published: (2025-02-01)

Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy
by: Shigeo Ohba, et al.
Published: (2025-01-01)

A rare IDH-Mutant glioma case: insights from single-cell transcriptomic analysis of tumor recurrences
by: Wen Li, et al.
Published: (2025-07-01)

Construction and validation of a prognostic nomogram model integrating machine learning-pathomics and clinical features in IDH-wildtype glioblastoma
by: Yaomin Li, et al.
Published: (2025-06-01)

Dissecting PTPN7‐driven aggressiveness in IDH‐wildtype astrocytomas: multi‐omics, clinical validation, and spatial transcriptomics for prognostic insights
by: Tung Liu, et al.
Published: (2025-05-01)

IDH1(R132H) Immunoexpression in Glioma
by: Nyan Saeed Omer, et al.
Published: (2023-03-01)

Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib
by: Ying Pang, et al.
Published: (2025-04-01)

Metabolic reprogramming in mutant IDH1 glioma cells.
by: Jose L Izquierdo-Garcia, et al.
Published: (2015-01-01)

Vorasidenib- A Paradigm Shift in IDH1- or IDH2-Mutant Low-Grade Glioma Treatment
by: Hurais Malik, et al.
Published: (2024-09-01)

Antisecretory factor as add-on treatment for newly diagnosed glioblastoma, IDH wildtype: study protocol for a randomized double-blind placebo-controlled trial
by: Erik Ehinger, et al.
Published: (2025-03-01)

Noninvasive prediction of Ki-67 expression level in IDH-wildtype glioblastoma using MRI histogram analysis: comparison and combination of MRI morphological features
by: Qiang Liang, et al.
Published: (2025-05-01)

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications
by: Kristian A. Choate, et al.
Published: (2024-10-01)

Comparison of Subjective and Objective Cognitive Function and Emotional State in Supratentorial Brain Tumors Before Surgery—Recognizing the Influence of Laterality
by: Lisa Schock, et al.
Published: (2025-02-01)

Dissecting the Immunological Microenvironment of Glioma Based on IDH Status: Implications for Immunotherapy
by: Miyu Kikuchi, et al.
Published: (2025-07-01)

IDH mutant glioma: the role of 2HG in seizure production and tumorigenesis
by: Hiroaki Nagashima, et al.
Published: (2025-01-01)

Novel metabolic subtypes in IDH-mutant gliomas: implications for prognosis and therapy
by: Peng Wang, et al.
Published: (2025-04-01)

Integration of MRI radiomics and germline genetics to predict the IDH mutation status of gliomas
by: Taishi Nakase, et al.
Published: (2025-06-01)

Vorasidenib for IDH-mutant grade 2 gliomas: clinical advances and future directions
by: Zhenjiang Pan, et al.
Published: (2025-06-01)

Isocitrate Dehydrogenase-Wildtype Glioma Adapts Toward Mutant Phenotypes and Enhanced Therapy Sensitivity Under D-2-Hydroxyglutarate Exposure
by: Geraldine Rocha, et al.
Published: (2025-06-01)

Predicting p53 Status in IDH‐Mutant Gliomas Using MRI‐Based Radiomic Model
by: Jiamin Li, et al.
Published: (2025-08-01)

A dual-genotype IDH-mutant infiltrating glioma, a real oligoastrocytoma in cerebral hemisphere
by: Jing Liu, PhD, et al.
Published: (2025-06-01)

Predicting IDH and 1p/19q molecular status of gliomas with multi-b values DWI
by: Shanshan Zhao, et al.
Published: (2025-07-01)

Proton therapy for adult type IDH-mutated glioma: Proglio-1, a multicenter retrospective study
by: Nicolas Goliot, et al.
Published: (2025-08-01)

Predictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective study
by: Bai Xuexue, et al.
Published: (2025-08-01)

Analysis of cerebrospinal fluid tumor-derived DNA to obviate biopsy of IDH-mutant brainstem glioma in an adult
by: Michael Youssef, et al.
Published: (2025-09-01)

Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas.
by: Michael E Berens, et al.
Published: (2019-01-01)

MRI transformer deep learning and radiomics for predicting IDH wild type TERT promoter mutant gliomas
by: Wenju Niu, et al.
Published: (2025-03-01)

The relationship between IDH, P53 mutations, MGMT methylation with characteristics in high grade glioma patients
by: Duc Anh Tran, et al.
Published: (2022-07-01)

Multidisciplinary quantitative and qualitative assessment of IDH-mutant gliomas with full diagnostic deep learning image reconstruction
by: Christer Ruff, et al.
Published: (2024-12-01)

Integrated Analysis of Cuproptosis Regulators Reveals Prognostic Significance and Therapeutic Targets in IDH1 Mutant Glioma
by: Yuxuan Luan, et al.
Published: (2025-03-01)

The Significance of IDH1 Mutations in Tumor-Associated Seizure in 60 Chinese Patients with Low-Grade Gliomas
by: Ruofei Liang, et al.
Published: (2013-01-01)

CD9 expression rivals IDH mutation as a prognostic marker in glioma: a novel nomogram approach
by: Yue Peng, et al.
Published: (2025-04-01)

IDH mutation and MGMT methylation status in glioblastoma and other gliomas patients: a Russian retrospective cohort study
by: Moez Eid, et al.
Published: (2025-05-01)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma.
by: Daniel Krell, et al.
Published: (2011-01-01)

Artificial Intelligent‐Enhanced Metabolite Profiling for Intraoperative IDH1 Genotyping in Glioma Using an Orthogonally Responsive SERS Probe
by: Hang Yin, et al.
Published: (2025-07-01)

Radiomic study on preoperative multi‐modal magnetic resonance images identifies IDH‐mutant TERT promoter‐mutant gliomas
by: Haoyu Wang, et al.
Published: (2023-02-01)

GENETIC BIOMARKERS OF GLIAL BRAIN TUMORS: IDH1 AND IDH2 MUTATIONS
by: M. Yu. Prokudin, et al.
Published: (2020-09-01)

Multipool-CEST and CEST-based pH assessment as predictive tools for glioma grading, IDH mutation, 1p/19q codeletion, and MGMT promoter methylation in gliomas
by: Xinli Zhang, et al.
Published: (2024-12-01)